126 related articles for article (PubMed ID: 9091298)
1. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation.
Nadal D; Guzman J; Fröhlich S; Braun DG
Exp Hematol; 1997 Mar; 25(3):223-31. PubMed ID: 9091298
[TBL] [Abstract][Full Text] [Related]
2. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.
Rooney CM; Smith CA; Heslop HE
Mol Med Today; 1997 Jan; 3(1):24-30. PubMed ID: 9021739
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes.
Mosier DE; Picchio GR; Baird SM; Kobayashi R; Kipps TJ
Cancer Res; 1992 Oct; 52(19 Suppl):5552s-5553s. PubMed ID: 1327510
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.
Khatri VP; Baiocchi RA; Bernstein ZP; Caligiuri MA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S129-36. PubMed ID: 9457408
[TBL] [Abstract][Full Text] [Related]
6. Suppressive effect of human natural killer cells on Epstein-Barr virus-induced immunoglobulin synthesis.
Kuwano K; Arai S; Munakata T; Tomita Y; Yoshitake Y; Kumagai K
J Immunol; 1986 Sep; 137(5):1462-8. PubMed ID: 3018077
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice.
Abedi MR; Linde A; Christensson B; Mackett M; Hammarström L; Smith CI
Int J Cancer; 1997 May; 71(4):624-9. PubMed ID: 9178818
[TBL] [Abstract][Full Text] [Related]
8. [Reconstitution of Hu-SCID mice transplanted with human tonsillar lymphocytes immunized with dengue virus-2 in vitro and its immune response].
Zuo L; Guo H; Zhang C
Zhonghua Yi Xue Za Zhi; 1996 Aug; 76(8):597-9. PubMed ID: 9275474
[TBL] [Abstract][Full Text] [Related]
9. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
Baiocchi RA; Caligiuri MA
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241
[TBL] [Abstract][Full Text] [Related]
10. Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells.
Nadal D; Albini B; Schläpfer E; Bernstein JM; Ogra PL
J Gen Virol; 1992 Jan; 73 ( Pt 1)():113-21. PubMed ID: 1309857
[TBL] [Abstract][Full Text] [Related]
11. Hematopathologic features of Epstein-Barr virus-induced human B-lymphoproliferation in mice with severe combined immunodeficiency. A model of lymphoproliferative diseases in immunocompromised patients.
Nakamine H; Okano M; Taguchi Y; Pirruccello SJ; Davis JR; Beisel KW; Kleveland K; Sanger WG; Fordyce RR; Purtilo DT
Lab Invest; 1991 Oct; 65(4):389-99. PubMed ID: 1656139
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.
Lay JD; Tsao CJ; Chen JY; Kadin ME; Su IJ
J Clin Invest; 1997 Oct; 100(8):1969-79. PubMed ID: 9329960
[TBL] [Abstract][Full Text] [Related]
15. EBV-induced human B cell lymphomas in hu-PBL-SCID mice.
Mosier DE; Picchio GR; Kirven MB; Garnier JL; Torbett BE; Baird SM; Kobayashi R; Kipps TJ
AIDS Res Hum Retroviruses; 1992 May; 8(5):735-40. PubMed ID: 1325170
[TBL] [Abstract][Full Text] [Related]
16. Post-transplantation lymphoproliferative disorders in Mexico: an aggressive clonal disease associated with Epstein-Barr virus type A.
Quintanilla-Martínez L; Lome-Maldonado C; Schwarzmann F; Gredler E; Reyes E; Angeles-Angeles A; Fend F
Mod Pathol; 1998 Feb; 11(2):200-8. PubMed ID: 9504692
[TBL] [Abstract][Full Text] [Related]
17. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus.
Chamat S; Walsh EE; Anderson D; Osta M; Awaraji C; Pan LZ; Ochi J; Shuey S; Brams P
J Infect Dis; 1999 Aug; 180(2):268-77. PubMed ID: 10395839
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
[TBL] [Abstract][Full Text] [Related]
19. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
